Natco Pharma Limited was incorporated in Hyderabad in the year 1981. Starting off as a single unit with 20 employees, Natco today has eight manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc. NATCO is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs)which makes finished dosage formulations and active pharmaceutical ingredients. The company's focus is primarily on niche therapeutic areas and complex products. It is the market leader in branded oncology medicines in India, and among the country's top three producers of hepatitis C drugs. It is well recognized for its innovation in pharmaceutical research and development (R&D). NATCO also exports its finished products through its subsidiaries in over 40 countries and collectively over 30 products across these geographies. ○ NATCOFARMA DO BRASIL (since 2011), ○ NATCO PHARMA CANADA INC. (since 2012), ○ NATCO PHARMA Asia Pte. Ltd. (since 2012) ○ NATCO Pharma Australia PTY Ltd. (since 2014).
Location: India
Employees: 1001-5000
Founded date: 1981
Investors 1
| Date | Name | Website |
| - | Multiples ... | multiplese... |
Mentions in press and media 25
| Date | Title | Description |
| 20.03.2026 | Here’s everything you need to know about Natco’s latest semaglutide injection launch | - |
| 17.03.2026 | Venture Catalysts exits hygiene startup Pee Safe with 9.6x return after OrbiMed-led $32 million round | Synopsis Other investors, including We Founder Circle, Alkemi Growth Capital and Alpha Capital, have also exited the company, Venture Catalysts founder Apoorva Ranjan Sharma told ET. Zerodha-backed Rainmatter and Natco Pharma continue to be... |
| 24.02.2026 | Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide | - |
| 12.02.2026 | NATCO Pharma Q3 PAT up | - |
| 03.02.2026 | Natco Pharma gets USFDA nod for cancer generic drug | - |
| 15.01.2026 | Pee Safe Secures $32 Million to Propel Global Hygiene Market Expansion | Pee Safe, a prominent hygiene and wellness brand, recently closed a $32 million Series C funding round. Healthcare-focused private equity firm OrbiMed led this significant investment. The capital injection targets ambitious growth. It will ... |
| 14.01.2026 | Pee Safe raises funding from OrbiMed to scale retail, quick-commerce push | Pee Safe co-founders (from left) Vikas Bagaria and Rithish Kumar Hygiene and wellness brand Pee Safe has secured capital in a growth funding round from healthcare-focused private equity firm OrbiMed, as it looks to expand its retail and qui... |
| 08.04.2025 | Natco Pharma to price Risdiplam at ₹15,900 | - |
| 12.02.2025 | Natco Pharma’s Q3 net down 37% to ₹132 crore | Natco Pharma’s consolidated net profit declined 37 per cent to ₹132 crore in the third quarter ended December 31, 2024, as against ₹212 crore in the same period last year, on account of a decrease in formulation exports. The total revenue o... |
| 23.01.2025 | Kotak Alternate Asset hits first close of third life sciences-focused PE fund | Credit: 123RF.com Kotak Alternate Asset Managers Ltd, the alternative asset management arm of Kotak Mahindra Group, said Thursday it has marked the first close of its third healthcare and life sciences-focused private equity fund. The firm ... |
Show more